ADMA Biologics, Inc. (ADMA) Class Action Lawsuit: Investors Face August 10, 2026, Deadline
PR Newswire
RADNOR, Pa., June 18, 2026
Did you buy ADMA securities between August 9, 2024 and March 25, 2026?Affected ADMA Investor SummaryWho: ADMA Biologics, Inc. (NASDAQ: ADMA)What: Securities fraud class action lawsuit filedClass Period: August 9, 2024 through March 25, 2026Deadline to Seek Lead Plaintiff Status: August 10, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's revenues and internal controls. Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery optionsRADNOR, Pa., June 18, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (ADMA Biologics) (NASDAQ: ADMA) on behalf of those who purchased or acquired ADMA Biologics securities between August 9, 2024 and March 25, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of New Jersey and is captioned Mazzarino v. ADMA Biologics, Inc., Case No. 2:26-cv-06918 (D.N.J.). Investors have until August 10, 2026, to file for lead plaintiff status.
